MDXH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MDxHealth SA is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is in a clear short-term downtrend, the latest quarter missed on revenue and EPS, guidance was cut, and the business is dealing with a strategic exit from Resolve UTI plus reimbursement-related uncertainty. Despite some bullish analyst ratings still in place, the recent target cuts and downgrade activity show deteriorating near-term confidence. I would not buy aggressively here; the better call is to hold and wait for clearer stabilization.
MDXH is technically weak despite being oversold. The MACD histogram is negative and expanding, which confirms bearish momentum. RSI_6 is 8.31, indicating extreme oversold conditions, but oversold alone is not enough to call a buy when trend structure is still bearish. The moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5, showing the stock remains below longer-term trend support. Pre-market price is 0.9511, down 3.41%, which keeps it below the S1 support at 1.195 and near the lower end of the range, with S2 at 0.89 as the next downside reference. The current setup suggests a weak trend and no confirmed reversal yet.
Revenue still grew 12.7% year over year in the latest quarter, showing the core business is not collapsing. Some analysts remain constructive on the long-term prostate cancer franchise and still keep Buy ratings despite lowering targets. The stock is deeply oversold technically, which could support a short-term bounce if selling pressure eases.
Q1 GAAP EPS was -$0.17, missing by $0.02, and revenue of $27.38M missed expectations by $3.42M. Gross margin fell to 60.7% from 63.8%, while operating expenses rose 19% to $23.9M. Management cut full-year revenue guidance by nearly 20% at the midpoint and is exiting the Resolve UTI business after a reimbursement setback from Novitas/Medicare-related recoupment concerns. Analysts have recently cut price targets sharply, and William Blair downgraded the stock to Market Perform. Hedge funds and insiders are neutral, and there is no congress trading signal or notable political buying support.
In Q1 2026, MDxHealth reported revenue of $27.38M, up 12.7% year over year, but below expectations by $3.42M. GAAP EPS came in at -$0.17 versus estimates by $0.02. Gross margin declined to 60.7% from 63.8% due to test-mix changes, and operating expenses rose 19% to $23.9M, driven by headcount and ExoDx acquisition-related costs. Overall, the latest quarter shows top-line growth, but profitability and operating leverage weakened, and the full-year outlook was reduced.
Recent analyst sentiment is mixed but clearly weaker than before. William Blair downgraded MDxHealth to Market Perform from Outperform with no target, citing the Q1 miss, guidance cut, and Resolve exit. Lake Street cut its target to $5 from $9 but kept Buy. TD Cowen lowered its target to $1.50 from $7 and kept Buy. BTIG reduced its target to $4 from $7 and kept Buy. The overall Wall Street view is that the core prostate cancer business may still have long-term value, but the near-term thesis has been damaged by reimbursement uncertainty, strategic restructuring, and disappointing execution.
